Glutamine supplementation in cystic fibrosis: A randomized placebo‐controlled trial. Issue 3 (27th December 2015)

• Record Type: Journal Article
• Authors: Forrester, Doug L.; Knox, Alan J.; Smyth, Alan R.; Barr, Helen L.; Simms, Rebecca; Pacey, Sarah J.; Pavord, Ian D.; Honeybourne, David; Dewar, Jane; Clayton, Andy; Fogarty, Andrew W.
• Is Part Of: Pediatric pulmonology. Volume 51:Issue 3(2016:Mar.)
• Page Start: 253
• Page End: 257
• Publication Date: 2015-12-27
• Subjects: glutamine -- cystic fibrosis -- infection -- nutrition; Pediatric respiratory diseases -- Periodicals; Pediatrics -- Periodicals; 618.922
• DOI: 10.1002/ppul.23370
• Languages: English
• ISSNs: 8755-6863

Abstract

Summary: Rationale: Pulmonary infection and malnutrition in cystic fibrosis are associated with decreased survival. Glutamine has a possible anti‐microbial effect, with a specific impact against Pseudomonas aeruginosa . We aimed to test the hypothesis that oral glutamine supplementation (21 g/day) for 8 weeks in adults with cystic fibrosis would decrease pulmonary inflammation and improve clinical status. Methods: The study design was a randomized double‐blind placebo‐controlled study design with an iso‐nitrogenous placebo. The primary analysis was intention to treat, and the primary outcome was change in induced sputum neutrophils. Results: Thirty‐nine individuals were recruited and thirty‐six completed the study. Glutamine supplementation had no impact on any of the outcome measures in the intention‐to‐treat analysis. In the per protocol analysis, glutamine supplementation was associated with an increase in induced sputum neutrophils ( P = 0.046), total cells ( P = 0.03), and in Pseudomonas isolation agar colony forming units ( P = 0.04) compared to placebo. Conclusions: There was no effect of glutamine supplementation on markers of pulmonary inflammation in the intention‐to‐treat analysis.Pediatr Pulmonol. 2016;51:253–257 . © 2015 Wiley Periodicals, Inc.